The study demonstrates the presence of two distinct metalloproteinases in vascular endothelial cells responsible for converting big endothelin-1 to active endothelin-1.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for distinct endothelial metalloproteinases in ET-1 maturation; leaves open their relevance to human vascular disease.
Incubation of big endothelin-1 (big ET-1(1-39] with either the cytosolic or membrane fraction obtained from cultured endothelial cells, resulted in an increase in immunoreactive-endothelin (IR-ET), which was markedly inhibited by metal chelators. Phosphoramidon, a metalloproteinase inhibitor, specifically suppressed the membrane fraction-induced increase in IR-ET, whereas the increase in IR-ET observed with the cytosolic fraction was not influenced by phosphoramidon. Reverse-phase (RP)-HPLC of the incubation mixture of big ET-1 with the cytosolic or membrane fraction revealed one major IR-ET component corresponding to the elution position of synthetic ET-1(1-21). Simultaneously, immunoreactivities like the C-terminal fragment (CTF22-39) of big ET-1 were present, as deduced from the RP-HPLC coupled with the radioimmunoassay for CTF. Our results indicate the presence of two types of metalloproteinases, which convert big ET-1 to ET-1 via a single cleavage between Trp21 and Val22, in vascular endothelial cells.
No takes yet. Share an insight, caveat, or question.
Matsumura et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: